Aurobindo gets FTC nod for Lannett Co acquisition
Synopsis Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic move, expected to conclude
Synopsis Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic move, expected to conclude by June 2026, will bolster Aurobindo's complex generics and controlled substances portfolio, enhance its US manufacturing capabilities with Lannett's Indiana facility, and is projected to immediately boost earnings per share.
The BriefWire